Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (9 amino acids) with the unusual distinction of being named for a physiological observation rather than designed for a target. The compound was characterized in the 1970s by the Schoenenberger-Monnier group at the University of Basel through one of the most elegant peptide discovery experiments in modern endocrinology: dialysate taken from the thalamic venous blood of sleeping rabbits could induce slow-wave EEG sleep when infused into recipient rabbits. Fractionation of this "sleep-promoting" blood eventually yielded a small peptide of nine amino acids that could reproduce the effect.
The naming reflected the initial mechanistic hypothesis: that DSIP specifically induced delta-wave sleep (the deepest, restorative slow-wave sleep). Subsequent research has nuanced this picture considerably. DSIP turned out to be far more complex than a simple "sleep peptide":
- Sleep effects: inconsistent across studies; the original rabbit findings have not been straightforwardly replicated in humans
- Stress modulation: effects on stress response systems
- Endocrine effects: modulates cortisol, LH, GH, ACTH
- Antioxidant properties: documented in multiple systems
- Opioid-system interactions: some evidence
- Pain modulation: investigated
- Circadian rhythm effects: on locomotor activity and other rhythms
A 2006 review by Kovalzon and Strekalova described DSIP as "a still unresolved riddle", a fair characterization that captures the gap between the compound's clear physiological activity and the uncertainty about its primary mechanism.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous DSIP | Variable, generally minutes (rapid initial clearance with slower secondary phase) |
| Intravenous DSIP | Bi-exponential clearance; minutes to hours |
| Oral DSIP (in unweaned rats) | Some uptake demonstrated; not feasible in adults |
What it does
Main effects
- Sleep modulation: original framing as a "sleep peptide"; rabbit cross-circulation experiments by Monnier/Schoenenberger group (1960s–70s) showed dialysate from sleeping rabbits could induce slow-wave EEG sleep in recipients; human sleep findings less consistent (Schneider-Helmert and Schoenenberger 1981, PMID 7028502): variable acute and delayed effects
- BBB penetration via specific saturable transport: unusual for a peptide of this size; high-affinity L-tryptophan-sensitive mechanism PMID: 2547200; highest brain uptake in caudate nucleus and hippocampus
- Stress modulation: effects on HPA axis, ACTH/cortisol responses to stressors; stress-protective effects in animal models
- Endocrine modulation: effects on LH, GH, ACTH, cortisol; broad regulatory peptide character
- Antioxidant effects: documented in multiple tissue systems; antioxidant gene expression modulation
- Circadian rhythm modulation: locomotor activity, neurotransmitter concentration, plasma protein rhythms
- Pain modulation: opioid-system interactions; effects on endogenous opioid release
- Pleiotropic regulatory peptide rather than dedicated sleep signal: Kovalzon and Strekalova 2006 review characterized DSIP as "a still unresolved riddle"
- DSIP-like material found in human breast milk: suggests biological role beyond CNS, significance unclear
What to watch for
Common side effects
- Mechanism remains incompletely characterized despite ~50 years of research: no clear primary mechanism; effects vary by species, dose, route, physiological state of recipient, brain region examined
- Inconsistent effects across studies and individuals: clinical effects are real but variable and modest
- No regulatory approval anywhere as therapeutic: distinguishes DSIP from Semax (Russian-approved), Selank (Russian-approved), and Cerebrolysin (50+ country approvals); pure research peptide
- The original "sleep peptide" framing oversimplifies: endogenous human plasma DSIP decreases at sleep onset (not increases); pattern may be the signal rather than simple induction; users should not expect dramatic sleep induction
- Injection site reactions (mild pain, redness with subcutaneous injection)
- Mild drowsiness: particularly with evening dosing
- Mild fatigue and headache: occasional
- Vivid dreams: some users report
- Notably ABSENT typical concerns: no documented dependence, tolerance, withdrawal, abuse potential, CNS depression at higher doses, cognitive impairment, or significant hormonal disruption (despite endocrine effects)
- Limited long-term human data: no multi-year controlled trials; ~50 years of research without resolution
- Possible bacterial origin: BLAST analysis aligns DSIP sequence with hypothetical Amycolatopsis coloradensis protein (curiosity, not concern)
- Quality concerns for research chemical sources (identity, concentration, purity; no approved formulation for reference)
- Sleep effects are inconsistent in humans: the original rabbit findings did not straightforwardly replicate; Schneider-Helmert and Schoenenberger 1981 showed acute and delayed effects with substantial variability, and the 2006 Kovalzon and Strekalova review characterized therapeutic applications as limited by that inconsistency
- Pregnancy, lactation, pediatric safety unestablished
- Not currently WADA-prohibited
Key facts
Key facts worth knowing
- DSIP is a synthetic nonapeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, MW 850 Da). It was first isolated from rabbit cerebral venous blood in 1974 through cross-circulation experiments, then characterized, sequenced, and synthesized between 1970–1977.
- Discovered by Schoenenberger and Monnier at the University of Basel through rabbit EEG studies showing that dialysate from sleeping rabbits could induce slow-wave sleep in recipient rabbits. The 1977 PNAS paper reported the complete amino acid analysis, sequence, synthesis, and activity of the nonapeptide. PMID: 568769
- Crosses the blood-brain barrier efficiently: unusual for a peptide of its size and composition. Schoenenberger et al. demonstrated CNS access in rabbits (1977), and Zlokovic et al. confirmed in 1988 that DSIP crosses the blood-CSF barrier. A 1989 study characterized the BBB transport as high affinity saturable mechanism at sites highly sensitive to L-tryptophan (the N-terminal residue of DSIP). PMID: 2547200
- Pleiotropic: Effects on sleep, stress, endocrine modulation, antioxidant systems, circadian rhythms, and pain pathways. No single unifying mechanism.
- Inconsistent sleep effects: Original rabbit findings did not straightforwardly replicate in humans. Schneider-Helmert and Schoenenberger 1981 (PMID 7028502) study on disturbed human sleep showed acute and delayed effects but with substantial variability. PMID: 7028502
- No regulatory approval anywhere as a therapeutic compound. Distinguishes from Semax (Russian-approved) and Selank (Russian-approved). DSIP is purely a research peptide despite ~50 years of investigation.
- "A still unresolved riddle": Kovalzon and Strekalova 2006 review in Journal of Neurochemistry characterized DSIP as having unresolved mechanistic and clinical questions despite extensive research. Original sleep findings difficult to reconcile with pleiotropic effects; multiple mechanisms documented but no clear primary mechanism; endogenous role uncertain; therapeutic applications limited by inconsistent effects. Kovalzon VM, Strekalova TV. Journal of Neurochemistry 2006;97(2):303-309
- Found endogenously in hypothalamus, limbic system, pituitary, and peripheral tissues. Circulates in blood in free and bound forms. DSIP-like material has been identified in human breast milk: suggests biological role beyond CNS, though significance unclear.
- WADA status: Not currently on the WADA Prohibited List (verify current status).
Legal status
Legal status
No regulatory approval anywhere as a therapeutic. Not a controlled substance. Not currently WADA-prohibited.